ScholarIQanswers from OpenAlex

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

PaperCitations, authors & open-access status

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma is a paper indexed in ScholarIQ from OpenAlex.

How many citations does B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma have?

ScholarIQcitation count

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma has 669 citations in the OpenAlex counts ScholarIQ stores.

When was B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma published?

ScholarIQyear

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma has 2013 year in the ScholarIQ index.

What is the open-access status of B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma?

ScholarIQoa status

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma has closed oa status in the ScholarIQ index.

What is the DOI of B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma?

ScholarIQdoi

The DOI for B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma is on the source record.

What is the PMID of B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma?

ScholarIQpmid

The PMID for B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma is on the source record.

What is the OpenAlex record for B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma?

ScholarIQopenalex

The OpenAlex for B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial